iShares Biotechnology ETF
561 hedge funds and large institutions have $5.46B invested in iShares Biotechnology ETF in 2017 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 195 increasing their positions, 175 reducing their positions, and 40 closing their positions.
118% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 40
65% more funds holding in top 10
Funds holding in top 10: 20 → 33 (+13)
11% more repeat investments, than reductions
Existing positions increased: 195 | Existing positions reduced: 175
8% more funds holding
Funds holding: 520 → 561 (+41)
8% more capital invested
Capital invested by funds: $5.06B → $5.46B (+$397M)
8.55% less ownership
Funds ownership: 177.99% → 169.44% (-8.6%)
17% less call options, than puts
Call options by funds: $875M | Put options by funds: $1.05B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Churchill Management
Los Angeles,
California
|
+$149M |
| 2 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
+$98.6M |
| 3 |
Morgan Stanley
New York
|
+$89.3M |
| 4 |
SIG
Senator Investment Group
New York
|
+$88.6M |
| 5 |
AL
Appaloosa LP
Short Hills,
New Jersey
|
+$69.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$181M |
| 2 |
JP Morgan Chase
New York
|
-$115M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$106M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$93.7M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$89.6M |
IBB Hedge Fund Activity: Q2 2017 in Review
561 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2017, worth a combined $5.46B — up 7.9% from $5.06B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new IBB positions and 40 closed out — a net gain of 47 holders — while 195 added to existing stakes and 175 trimmed.
The largest buyer was Churchill Management, opening a new position worth an estimated $149M. The largest seller was Goldman Sachs, cutting an estimated $181M.
- 561 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2017, up from 520 in Q1 2017.
- Funds reported $5.46B of iShares Biotechnology ETF stock for Q2 2017, up 7.9% quarter-over-quarter.
- 87 funds opened new iShares Biotechnology ETF positions in Q2 2017 and 40 closed out, a net change of +47 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2017 was Churchill Management, an estimated $149M added.
- The largest iShares Biotechnology ETF seller in Q2 2017 was Goldman Sachs, an estimated $181M sold.
Based on aggregated 13F filings for Q2 2017.